Immunomodulatory properties of farnesoids: The new steroids?

Current Medicinal Chemistry

Volumn 20, Issue 10, 2013, Pages 1218-1224

  Mor, A ^a,b   Aizman, E ^b   Chapman, J ^c   Kloog, Y ^b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TEL AVIV UNIVERSITY   (Israel)

^c SHEBA MEDICAL CENTER   (Israel)

Author keywords

Autoimmunity; Farnesylthiosalisylic acid; Inflammation

Indexed keywords

ANTIINFLAMMATORY AGENT; FARNESYLTHIOSALISYLIC ACID; IMMUNOMODULATING AGENT; RAS PROTEIN; UNCLASSIFIED DRUG;

ALLERGY; ANTIINFLAMMATORY ACTIVITY; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; ATHEROSCLEROSIS; AUTOIMMUNITY; CELLULAR IMMUNITY; DIABETES MELLITUS; GUILLAIN BARRE SYNDROME; HUMAN; HUMORAL IMMUNITY; IMMUNOMODULATION; INNATE IMMUNITY; LEUKOCYTE ACTIVATION; LYMPHOCYTE; MAST CELL DEGRANULATION; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MULTIPLE SCLEROSIS; MYOCARDITIS; NEPHRITIS; NONHUMAN; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; AUTOIMMUNE DISEASES; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; FARNESOL; HUMANS; PROTEIN BINDING; RAS PROTEINS; SALICYLATES;

EID: 84877959969     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867311320100002     Document Type: Article

References (48)

1. Kloog Y. Cox A.D. Ras inhibitors: potential for cancer therapeutics. Mol Med Today 2000 6 398-402.
2. Downward J. Targeting Ras signaling pathways in cancer therapy. Nat Rev Cancer 2003 3 11-22. (Pubitemid 37328883)
3. Cox A.D. Der C.J. Ras family signaling: Therapeutic targeting. Cancer Biol Ther 2002 1 599-606.
4. Hanahan D. Weinberg R.A. The hallmarks of cancer. Cell 2000 100 57-70. (Pubitemid 30046295)
5. Philips M.R. Cox A.D. Geranylgeranyltransferase I as a target for anti-cancer drugs. J Clin Invest 2007 117 1223-1225. (Pubitemid 46718409)
6. Hancock J.F. Parton R.G. Ras plasma membrane signaling platforms. Biochem J 2005 389 1-11. (Pubitemid 40978001)
7. Silvius J.R. Bhagatji P. Leventis R. Terrone D. K-ras4B and prenylated proteins lacking second signals associate dynamically with cellular membranes. Mol Biol Cell 2006 17 192-202. (Pubitemid 43049473)
8. Nancy V. Callebaut I. El-Marjou A. de Gunzburg J. The subunit of retinal rod cGMP phosphodiesterase regulates the membrane association of Ras and Rap GTPases. J Biol Chem 2002 277 15076-15084. (Pubitemid 34952585)
9. Philips M.R. Ras hitchhikes on PDE6. Nat Cell Biol 2012 14 128-129.
10. Chandra A. Grecco H.E. Pisupati V. Perera D. Cassidy L. Skoulidis F. Ismail S.A. Hedberg C. Hanzal-Bayer M. Venkitaraman A.R. Wittinghofer A. Bastiaens P.I. The GDI-like solubilizing factor PDE sustains the spatial organization and signalling of Ras family proteins. Nat Cell Biol 2011 14 148-158.
11. Rotblat B. Ehrlich M. Haklai R. Kloog Y. The Ras inhibitor farnesylthiosalicylic acid (Salirasib) disrupts the spatiotemporal localization of active Ras: a potential treatment for cancer. Methods Enzymol 2008 439 467-489.
12. Farin K. Schokoroy S. Haklai R. Cohen-Or I. Elad-Sfadia G. Reyes-Reyes M.E. Bates P.J. Cox A.D. Kloog Y. Pinkas-Kramarski R. Oncogenic synergism between ErbB1 nucleolin and mutant Ras. Cancer Res 2011 71 2140-2151.
13. Bhagatji P. Leventis R. Rich R. Lin C.J. Silvius J.R. Multiple cellular proteins modulate the dynamics of K-ras association with the plasma membrane. Biophys J 2010 99 3327-3335.
14. Bustinza-Linares E. Kurzrock R. Tsimberidou A.M. Salirasib in the treatment of pancreatic cancer. Future Oncol 2010 6 885-891.
15. Marciano D. Ben-Baruch G. Marom M. Egozi Y. Haklai R. Kloog Y. Farnesyl derivatives of rigid carboxylic acids-inhibitors of ras-dependent cell growth. J Med Chem 1995 38 1267-1272.
16. Aharonson Z. Gana-Weisz M. Varsano T. Haklai R. Marciano D. Kloog Y. Stringent structural requirements for anti-Ras activity of S-prenyl analogues. Biochim Biophys Acta 1998 1406 40-50. (Pubitemid 28162309)
17. Goldberg L. Haklai R. Bauer V. Heiss A. Kloog Y. New derivatives of farnesylthiosalicylic acid (salirasib) for cancer treat-ment: farnesylthiosalicylamide inhibits tumor growth in nude mice models. J Med Chem 2009 52 197-205.
18. Mor A. Philips M.R. Pillinger M.H. The role of Ras signaling in lupus T lymphocytes: biology and pathogenesis. Clin Immunol 2007 125 215-223. (Pubitemid 350116716)
19. Mor A. Ben-Moshe O. Mekori Y.A. Kloog Y. Inhibitory effect of farnesylthiosalicylic acid on mediators release by mast cells: preferential inhibition of prostaglandin D2 and tumor necrosis factor- release. Inflammation 2011 34 314-318.
20. Rapoport M.J. Bloch O. Amit-Vasina M. Yona. E. Molad Y. Constitutive abnormal expression of RasGRP-1 isoforms and low expression of PARP-1 in patients with systemic lupus erythematosus. Lupus 2011 20 1501-1509.
21. Katzav A. Kloog Y. Korczyn A.D. Niv H. Karussis D.M. Wang N. Rabinowitz R. Blank M. Shoenfeld Y. Chapman J. Treatment of MRL/lpr mice a genetic autoimmune model with the Ras inhibitor farnesylthiosalicylate (FTS). Clin Exp Immunol 2001 126 570-577. (Pubitemid 34008734)
22. Chapman J. Rand J.H. Brey R.L. Levine S.R. Blatt I. Khamashta M.A. Shoenfeld Y. Non-stroke neurological syndromes associated with antiphospholipid antibodies: evaluation of clinical and experimental studies. Lupus 2003 12 514-517. (Pubitemid 36890142)
23. Brey R.L. Chapman J. Levine S.R. Ruiz-Irastorza G. Derksen R.H. Khamashta M. Shoenfeld Y. Stroke and the antiphospholipid syndrome: consensus meeting Taormina 2002. Lupus 2003 12 508-513.
24. Katzav A. Kloog Y. Korczyn A.D. Niv H. Karussis D.M. Wang N. Rabinowitz R. Blank M. Shoenfeld Y. Chapman J. Treatment of MRL/lpr mice a genetic autoimmune model with the Ras inhibitor farnesylthiosalicylate (FTS). Clin Exp Immunol 2001 126 570-577. (Pubitemid 34008734)
25. Yuki N. Hartung H.P. Guillain-Barre syndrome. N Engl J Med 2012 366 2294-2304.
26. Kafri M. Kloog Y. Korczyn A.D. Ferdman-Aronovich R. Drory V. Katzav A. Wirguin I. Chapman J. Inhibition of Ras attenuates the course of experimental autoimmune neuritis. J Neuroimmunol 2005 168 46-55. (Pubitemid 41398186)
27. Compston A. Coles A. Multiple sclerosis. Lancet 2002 359 1221-1231. (Pubitemid 34304266)
28. Karussis D. Abramsky O. Grigoriadis N. Chapman J. Mizrachi-Koll R. Niv H. Kloog Y. The Ras-pathway inhibitor S-trans-trans-farnesylthiosalicylic acid suppresses experimental allergic encephalomyelitis. J Neuroimmunol 2001 120 1-9. (Pubitemid 33016718)
29. Aizman E. Mor A. Chapman J. Assaf Y. Kloog Y. The combined treatment of Copaxone and Salirasib attenuates experimental autoimmune encephalomyelitis (EAE) in mice. J Neuroimmunol 2010 229 192-203.
30. Pando R. Barshack I. Raz A. Luboshits G. Haklai R. Maysel-Auslender S. Kloog Y. Keren G. George J. The Ras antagonist farnesylthiosalicylic acid ameliorates experimental myocarditis in the rat. Cardiovasc Pathol 2010 19 94-101.
31. Oron T. Elad-Sfadia G. Haklai R. Aizman E. Brazowski E. Kloog Y. Reif S. Prevention of induced colitis in mice by the ras antagonist farnesylthiosalicylic acid. Dig Dis Sci 2012 57 320-326.
32. Tritt M. Sgouroudis E. d'Hennezel E. Albanese A. Piccirillo C.A. Functional waning of naturally occurring CD4+ regulatory Tcells contributes to the onset of autoimmune diabetes. Diabetes 2008 57 113-123.
33. Sakaguchi S. Yamaguchi T. Nomura T. Ono M. Regulatory T cells and immune tolerance. Cell 2008 133 775-787. (Pubitemid 351707693)
34. Mor A. Kloog Y. Keren G. George J. Ras inhibition increases the frequency and function of regulatory T cells and attenuates type-1 diabetes in non-obese diabetic mice. Eur J Pharmacol 2009 616 301-305.
35. Aizman E. Mor A. George J. Kloog Y. Ras inhibition attenuates pancreatic cell death and experimental type 1 diabetes: possible role of regulatory T cells. Eur J Pharmacol 2010 643 139-144.
36. Reaven G.M. Role of insulin resistance in human disease. Diabetes 1988 37 1595-1607. (Pubitemid 19004941)
37. Mor A. Aizman E. George J. Kloog Y. Ras inhibition induces insulin sensitivity and glucose uptake. PLoS One 2011 6:e21712.
38. Mor A. Haklai R. Ben-Moshe O. Mekori Y.A. Kloog Y. Inhibition of contact sensitivity by farnesylthiosalicylic acid-amide a potential Rap1 inhibitor. J Invest Dermatol 2011 131 2040-2048.
39. Mor A. Aizman E. Kloog Y. Celecoxib Enhances the Antiinflammatory Effects of Farnesylthiosalicylic Acid on T Cells Independent of Prostaglandin E2 Production. Inflammation 2012 Jun 12 [Epub ahead of print].
40. Tisch-Idelson D. Sharabani M. Kloog Y. Aviram I. Stimulation of neutrophils by prenylcysteine analogs: Ca(2+) release and influx. Biochim Biophys Acta 1999 1451 187-195. (Pubitemid 29364258)
41. Ross R. Atherosclerosis: an inflammatory condition. N Engl J Med 1999 340 115-126.
42. George J. Afek A. Keren P. Herz I. Goldberg I. Haklai R. Kloog Y. Keren G. Functional inhibition of Ras by S-transtransfarnesyl thiosalicylic acid attenuates atherosclerosis in apolipoprotein E knockout mice. Circulation 2002 105 2416-2422. (Pubitemid 34556395)
43. Pando R. Cheporko Y. Haklai R. Maysel-Auslender S. Keren G. George J. Porat E. Sagie A. Kloog Y. Hochhauser E. Ras inhibition attenuates myocardial ischemia-reperfusion injury. Biochem Pharmacol 2009 77 1593-1601.
44. Reif S. Aeed H. Shilo Y. Reich R. Kloog Y. Kweon Y.O. Bruck R. Treatment of thioacetamide-induced liver cirrhosis by the Ras antagonist farnesylthiosalicylic acid. J Hepatol 2004 41 235-241. (Pubitemid 39177627)
45. Nevo Y. Aga-Mizrachi S. Elmakayes E. Yanay N. Ettinger K. Elbaz M. Brunschwig Z. Dadush O. Elad-Sfadia G. Haklai R. Kloog Y. Chapman J. Reif S. The Ras antagonist farnesylthiosalicylic acid (FTS) decreases fibrosis and improves muscle strength in dy/dy mouse model of muscular dystrophy. PLoS One 2011 6:e18049.
46. Clarke H.C. Kocher H.M. Khwaja A. Kloog Y. Cook H.T. Hendry B.M. Ras antagonist farnesylthiosalicylic acid (FTS) reduces glomerular cellular proliferation and macrophage number in rat thy-1 nephritis. J Am Soc Nephrol 2003 14 848-854. (Pubitemid 36359266)
47. Strehl C. Spies C.M. Buttgereit F. Pharmacodynamics of glucocorticoids. Clin Exp Rheumatol 2011 29 S13-S18.
48. Marin M. Manez S. Pharmacological interventions on asymmetric dimethylarginine a clinical marker of vascular disease. Curr Med Chem 2011 18 714-724.